Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    LY2812176
Show Display Options
Rank Status Study
1 Recruiting A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: DKN-01 300 mg;   Drug: DKN-01 600 mg;   Drug: Standard of Care
2 Recruiting A Study of DKN-01 in Combination With Paclitaxel
Conditions: Esophageal Neoplasms;   Adenocarcinoma of the Gastroesophageal Junction;   Gastroesophageal Cancer
Interventions: Drug: DKN-01;   Drug: Paclitaxel
3 Completed A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
Conditions: Multiple Myeloma;   Solid Tumors;   Non-Small Cell Lung Cancer
Intervention: Drug: DKN-01

Indicates status has not been verified in more than two years